- Home
- Publications
- Publication Search
- Publication Details
Title
Talazoparib: First Global Approval
Authors
Keywords
-
Journal
DRUGS
Volume 78, Issue 18, Pages 1939-1946
Publisher
Springer Nature
Online
2018-11-30
DOI
10.1007/s40265-018-1026-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside
- (2018) Anita A. Turk et al. CANCER
- Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial
- (2018) J Ettl et al. ANNALS OF ONCOLOGY
- Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+).
- (2018) Jennifer Keating Litton et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA).
- (2018) Wolfgang Eiermann et al. JOURNAL OF CLINICAL ONCOLOGY
- EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation.
- (2018) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- Talapro-2: A 2-part, placebo-controlled phase 3 study of talazoparib (TALA) with background enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair deficiencies.
- (2018) Neeraj Agarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- 305PExposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial
- (2018) Y Yu et al. ANNALS OF ONCOLOGY
- 306PExposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials
- (2018) M Elmeliegy et al. ANNALS OF ONCOLOGY
- Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial
- (2018) S.A. Hurvitz et al. EUROPEAN JOURNAL OF CANCER
- Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
- (2017) Johann de Bono et al. Cancer Discovery
- Abstract CT011: Safety and efficacy results from a phase I dose-escalation trial of the PARP inhibitor talazoparib in combination with either temozolomide or irinotecan in patients with advanced malignancies
- (2016) Zev A. Wainberg et al. CANCER RESEARCH
- A phase 1/2 study of talazoparib (BMN 673), an oral poly(ADP-ribose) polymerase inhibitor, plus temozolomide in children with refractory or recurrent malignancies: A Children's Oncology Group phase 1 consortium study (ADVL1411)
- (2016) E.S. Schafer et al. EUROPEAN JOURNAL OF CANCER
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started